The Medicines (MDCO) Lifted to “Hold” at ValuEngine

ValuEngine upgraded shares of The Medicines (NASDAQ:MDCO) from a sell rating to a hold rating in a report released on Friday morning.

Several other equities analysts have also commented on the stock. Chardan Capital reissued a buy rating and issued a $85.00 target price (up from $80.00) on shares of The Medicines in a report on Tuesday, August 29th. Jefferies Group reissued a buy rating and issued a $54.00 target price on shares of The Medicines in a report on Thursday, October 26th. Oppenheimer set a $50.00 target price on shares of The Medicines and gave the company a hold rating in a report on Thursday, October 26th. Guggenheim initiated coverage on shares of The Medicines in a report on Monday, October 23rd. They issued a buy rating and a $45.00 target price on the stock. Finally, Zacks Investment Research lowered shares of The Medicines from a hold rating to a strong sell rating in a report on Tuesday, October 10th. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and nine have assigned a buy rating to the company’s stock. The company has a consensus rating of Buy and a consensus price target of $53.67.

The Medicines (NASDAQ MDCO) traded down $0.50 during mid-day trading on Friday, reaching $28.50. 1,412,100 shares of the company’s stock traded hands, compared to its average volume of 1,431,329. The company has a debt-to-equity ratio of 3.42, a quick ratio of 1.79 and a current ratio of 2.31. The Medicines has a 52-week low of $27.77 and a 52-week high of $55.95.

The Medicines (NASDAQ:MDCO) last released its earnings results on Wednesday, October 25th. The company reported ($0.42) EPS for the quarter, beating the consensus estimate of ($1.37) by $0.95. The Medicines had a negative net margin of 767.94% and a negative return on equity of 174.68%. The firm had revenue of $16.87 million for the quarter, compared to analyst estimates of $26.06 million. During the same period last year, the firm earned ($0.64) EPS. The business’s quarterly revenue was down 55.1% compared to the same quarter last year. equities research analysts forecast that The Medicines will post -8.86 earnings per share for the current fiscal year.

In related news, Director Alexander J. Denner purchased 170,000 shares of the firm’s stock in a transaction that occurred on Wednesday, November 29th. The shares were bought at an average cost of $30.03 per share, with a total value of $5,105,100.00. Following the acquisition, the director now owns 6,663 shares of the company’s stock, valued at approximately $200,089.89. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders own 8.22% of the company’s stock.

Institutional investors have recently made changes to their positions in the stock. Zurcher Kantonalbank Zurich Cantonalbank grew its holdings in shares of The Medicines by 10.6% during the 2nd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 2,753 shares of the company’s stock valued at $105,000 after purchasing an additional 264 shares during the last quarter. Quantbot Technologies LP acquired a new stake in The Medicines during the 3rd quarter worth approximately $171,000. First Mercantile Trust Co. boosted its position in The Medicines by 2.5% during the 2nd quarter. First Mercantile Trust Co. now owns 4,767 shares of the company’s stock worth $181,000 after buying an additional 114 shares during the period. SG Americas Securities LLC acquired a new stake in The Medicines during the 3rd quarter worth approximately $198,000. Finally, Bluefin Trading LLC acquired a new stake in The Medicines during the 2nd quarter worth approximately $214,000.

TRADEMARK VIOLATION NOTICE: This article was first reported by Week Herald and is owned by of Week Herald. If you are accessing this article on another website, it was illegally copied and reposted in violation of United States and international copyright law. The legal version of this article can be read at https://weekherald.com/2017/12/04/the-medicines-mdco-lifted-to-hold-at-valuengine.html.

The Medicines Company Profile

The Medicines Company is a global biopharmaceutical company. The Company is focused on advancing the treatment of acute and intensive care patients through the delivery of medicines to the hospital marketplace around the world. It markets Angiomax (bivalirudin), Ionsys (fentanyl iontophoretic transdermal system), Minocin (minocycline) for injection and Orbactiv (oritavancin).

To view ValuEngine’s full report, visit ValuEngine’s official website.

Analyst Recommendations for The Medicines (NASDAQ:MDCO)

Receive News & Ratings for The Medicines Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for The Medicines Company and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply